<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:dt="uuid:C2F41010-65B3-11d1-A29F-00AA00C14882"
xmlns:m="http://schemas.microsoft.com/office/2004/12/omml"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 15">
<meta name=Originator content="Microsoft Word 15">
<link rel=File-List href="MS_Refs_files/filelist.xml">
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Chakraborty, Apurba</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>Chakraborty, Apurba</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>17</o:TotalTime>
  <o:Created>2022-10-11T15:21:00Z</o:Created>
  <o:LastSaved>2022-10-11T15:21:00Z</o:LastSaved>
  <o:Pages>5</o:Pages>
  <o:Words>2287</o:Words>
  <o:Characters>13038</o:Characters>
  <o:Company>BlueCross BlueShield Association</o:Company>
  <o:Lines>108</o:Lines>
  <o:Paragraphs>30</o:Paragraphs>
  <o:CharactersWithSpaces>15295</o:CharactersWithSpaces>
  <o:Version>16.00</o:Version>
 </o:DocumentProperties>
 <o:CustomDocumentProperties>
  <o:MSIP_Label_6a772476-9fad-428e-bd1c-a3a17c3bbc75_Enabled dt:dt="string">true</o:MSIP_Label_6a772476-9fad-428e-bd1c-a3a17c3bbc75_Enabled>
  <o:MSIP_Label_6a772476-9fad-428e-bd1c-a3a17c3bbc75_SetDate dt:dt="string">2022-10-11T15:03:15Z</o:MSIP_Label_6a772476-9fad-428e-bd1c-a3a17c3bbc75_SetDate>
  <o:MSIP_Label_6a772476-9fad-428e-bd1c-a3a17c3bbc75_Method dt:dt="string">Standard</o:MSIP_Label_6a772476-9fad-428e-bd1c-a3a17c3bbc75_Method>
  <o:MSIP_Label_6a772476-9fad-428e-bd1c-a3a17c3bbc75_Name dt:dt="string">Confidential Information</o:MSIP_Label_6a772476-9fad-428e-bd1c-a3a17c3bbc75_Name>
  <o:MSIP_Label_6a772476-9fad-428e-bd1c-a3a17c3bbc75_SiteId dt:dt="string">bb087376-1284-4173-9385-a6766cdfef8c</o:MSIP_Label_6a772476-9fad-428e-bd1c-a3a17c3bbc75_SiteId>
  <o:MSIP_Label_6a772476-9fad-428e-bd1c-a3a17c3bbc75_ActionId dt:dt="string">105bdb03-39d1-4b28-8207-b208ce9ad9e6</o:MSIP_Label_6a772476-9fad-428e-bd1c-a3a17c3bbc75_ActionId>
  <o:MSIP_Label_6a772476-9fad-428e-bd1c-a3a17c3bbc75_ContentBits dt:dt="string">0</o:MSIP_Label_6a772476-9fad-428e-bd1c-a3a17c3bbc75_ContentBits>
 </o:CustomDocumentProperties>
 <o:OfficeDocumentSettings>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=themeData href="MS_Refs_files/themedata.thmx">
<link rel=colorSchemeMapping href="MS_Refs_files/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:SpellingState>Clean</w:SpellingState>
  <w:GrammarState>Clean</w:GrammarState>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="false"
  DefSemiHidden="false" DefQFormat="false" DefPriority="99"
  LatentStyleCount="376">
  <w:LsdException Locked="false" Priority="0" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 9"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="header"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footer"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index heading"/>
  <w:LsdException Locked="false" Priority="35" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of figures"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope return"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="line number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="page number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of authorities"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="macro"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="toa heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 5"/>
  <w:LsdException Locked="false" Priority="10" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Closing"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Signature"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="true"
   UnhideWhenUsed="true" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Message Header"/>
  <w:LsdException Locked="false" Priority="11" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Salutation"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Date"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Note Heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Block Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Hyperlink"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="FollowedHyperlink"/>
  <w:LsdException Locked="false" Priority="22" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Document Map"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Plain Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="E-mail Signature"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Top of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Bottom of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal (Web)"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Acronym"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Cite"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Code"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Definition"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Keyboard"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Preformatted"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Sample"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Typewriter"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Variable"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Table"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation subject"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="No List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Contemporary"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Elegant"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Professional"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Balloon Text"/>
  <w:LsdException Locked="false" Priority="39" Name="Table Grid"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Theme"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" QFormat="true"
   Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" QFormat="true"
   Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" QFormat="true"
   Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" QFormat="true"
   Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" QFormat="true"
   Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" QFormat="true"
   Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" SemiHidden="true"
   UnhideWhenUsed="true" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/>
  <w:LsdException Locked="false" Priority="41" Name="Plain Table 1"/>
  <w:LsdException Locked="false" Priority="42" Name="Plain Table 2"/>
  <w:LsdException Locked="false" Priority="43" Name="Plain Table 3"/>
  <w:LsdException Locked="false" Priority="44" Name="Plain Table 4"/>
  <w:LsdException Locked="false" Priority="45" Name="Plain Table 5"/>
  <w:LsdException Locked="false" Priority="40" Name="Grid Table Light"/>
  <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Mention"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Smart Hyperlink"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Hashtag"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Unresolved Mention"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Smart Link"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536869121 1107305727 33554432 0 415 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-469750017 -1073732485 9 0 511 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612049 1073772795 0 0 159 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
h1
	{mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 1 Char";
	mso-style-next:Normal;
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:15.0pt;
	font-family:"Arial Black",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#2F5496;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:0pt;
	font-weight:normal;
	mso-bidi-font-weight:bold;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 1";
	mso-ansi-font-size:15.0pt;
	mso-bidi-font-size:15.0pt;
	font-family:"Arial Black",sans-serif;
	mso-ascii-font-family:"Arial Black";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Arial Black";
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#2F5496;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-bidi-font-weight:bold;}
span.SpellE
	{mso-style-name:"";
	mso-spl-e:yes;}
span.GramE
	{mso-style-name:"";
	mso-gram-e:yes;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
.MsoPapDefault
	{mso-style-type:export-only;
	margin-bottom:8.0pt;
	line-height:107%;}
 /* Page Definitions */
 @page
	{mso-footnote-separator:url("MS_Refs_files/header.htm") fs;
	mso-footnote-continuation-separator:url("MS_Refs_files/header.htm") fcs;
	mso-endnote-separator:url("MS_Refs_files/header.htm") es;
	mso-endnote-continuation-separator:url("MS_Refs_files/header.htm") ecs;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 @list l0
	{mso-list-id:1989049787;
	mso-list-type:hybrid;
	mso-list-template-ids:1644472748 67698703 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;}
@list l0:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l0:level2
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:-.25in;}
@list l0:level3
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	margin-left:1.25in;
	text-indent:-9.0pt;}
@list l0:level4
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:-.25in;}
@list l0:level5
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.25in;}
@list l0:level6
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	margin-left:2.75in;
	text-indent:-9.0pt;}
@list l0:level7
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:-.25in;}
@list l0:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:-.25in;}
@list l0:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	margin-left:4.25in;
	text-indent:-9.0pt;}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin-top:0in;
	mso-para-margin-right:0in;
	mso-para-margin-bottom:8.0pt;
	mso-para-margin-left:0in;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="2050"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="2"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-US style='tab-interval:.5in;word-wrap:break-word'>

<div class=WordSection1>

<h1 style='margin:0in;mso-add-space:auto'>References <o:p></o:p></h1>

<p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
8.0pt;margin-left:.25in;mso-add-space:auto;text-indent:-.25in;line-height:107%;
mso-list:l0 level1 lfo1'><![if !supportLists]><span style='mso-fareast-font-family:
Calibri'><span style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span class=SpellE>Kappos</span> L, Bar-Or A,
Cree BAC, Fox RJ, <span class=SpellE>Giovannoni</span> G, Gold R, <span
class=SpellE>Vermersch</span> P, Arnold DL, <span class=SpellE>Arnould</span>
S, <span class=SpellE>Scherz</span> T, Wolf C, <span class=SpellE>Wallström</span>
E, Dahlke F; EXPAND Clinical Investigators. Siponimod versus placebo in
secondary progressive multiple sclerosis (EXPAND): a double-blind, <span
class=SpellE>randomised</span>, phase 3 study. Lancet. 2018 Mar
31;391(10127):1263-1273. <span class=SpellE>doi</span>:
10.1016/S0140-6736(18)30475-6. <span class=SpellE>Epub</span> 2018 Mar 23.
Erratum in: Lancet. 2018 Nov 17;392(10160):2170. PubMed PMID: 29576505.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]>Kapoor
R, Ho PR, Campbell N, Chang I, <span class=SpellE>Deykin</span> A, Forrestal F,
Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, <span
class=SpellE>Havrdová</span> EK, Jeffery D, Miller A, <span class=SpellE>Sellebjerg</span>
F, <span class=SpellE>Cadavid</span> D, <span class=SpellE>Mikol</span> D,
Steiner D; ASCEND investigators. Effect of natalizumab on disease progression
in secondary progressive multiple sclerosis (ASCEND): a phase 3, <span
class=SpellE>randomised</span>, double-blind, placebo-controlled trial with an
open-label extension. Lancet Neurol. 2018 May;17(5):405-415. <span
class=SpellE>doi</span>: 10.1016/S1474-4422(18)30069-3. <span class=SpellE>Epub</span>
2018 Mar 12. PubMed PMID: 29545067.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
class=SpellE>Comi</span> G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P, <span
class=SpellE>Centonze</span> D, <span class=SpellE>Pozzilli</span> C, <span
class=SpellE>Saccà</span> F, Bergh FT, <span class=SpellE>Bartezaghi</span> M, <span
class=SpellE>Turrini</span> R, <span class=SpellE>Filippi</span> M; Golden
Study Group. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI,
and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month,
open-label, rater-blinded, <span class=SpellE>randomised</span>, <span
class=SpellE>multicentre</span> study (the GOLDEN study). J Neurol. 2017
Dec;264(12):2436-2449. <span class=SpellE>doi</span>:
10.1007/s00415-017-8642-5. <span class=SpellE>Epub</span> 2017 Oct 23. PubMed
PMID: 29063244; PubMed Central PMCID: PMC5688215.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
class=SpellE>Montalban</span> X, Hauser SL, <span class=SpellE>Kappos</span> L,
Arnold DL, Bar-Or A, <span class=SpellE>Comi</span> G, de <span class=SpellE>Seze</span>
J, <span class=SpellE>Giovannoni</span> G, Hartung HP, Hemmer B, Lublin F, <span
class=SpellE>Rammohan</span> KW, <span class=SpellE>Selmaj</span> K, <span
class=SpellE>Traboulsee</span> A, Sauter A, <span class=SpellE>Masterman</span>
D, <span class=SpellE>Fontoura</span> P, <span class=SpellE>Belachew</span> S, <span
class=SpellE>Garren</span> H, <span class=SpellE>Mairon</span> N, Chin P, <span
class=SpellE>Wolinsky</span> JS; ORATORIO Clinical Investigators. Ocrelizumab
versus Placebo in Primary Progressive Multiple Sclerosis. N <span class=SpellE>Engl</span>
J Med. 2017 Jan 19;376(3):209-220. <span class=SpellE>doi</span>:
10.1056/NEJMoa1606468. <span class=SpellE>Epub</span> 2016 Dec 21. PubMed PMID:
28002688.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]>Hauser
SL, Bar-Or A, <span class=SpellE>Comi</span> G, <span class=SpellE>Giovannoni</span>
G, Hartung HP, Hemmer B, Lublin F, <span class=SpellE>Montalban</span> X, <span
class=SpellE>Rammohan</span> KW, <span class=SpellE>Selmaj</span> K, <span
class=SpellE>Traboulsee</span> A, <span class=SpellE>Wolinsky</span> JS, Arnold
DL, <span class=SpellE>Klingelschmitt</span> G, <span class=SpellE>Masterman</span>
D, <span class=SpellE>Fontoura</span> P, <span class=SpellE>Belachew</span> S,
Chin P, <span class=SpellE>Mairon</span> N, <span class=SpellE>Garren</span> H,
<span class=SpellE>Kappos</span> L; OPERA I and OPERA II Clinical
Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple
Sclerosis. N <span class=SpellE>Engl</span> J Med. 2017 Jan 19;376(3):221-234. <span
class=SpellE>doi</span>: 10.1056/NEJMoa1601277. <span class=SpellE>Epub</span>
2016 Dec 21. PubMed PMID: 28002679.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>6.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]>Lublin
F, Miller DH, Freedman MS, Cree BAC, <span class=SpellE>Wolinsky</span> JS,
Weiner H, <span class=SpellE>Lubetzki</span> C, Hartung HP, <span class=SpellE>Montalban</span>
X, <span class=SpellE>Uitdehaag</span> BMJ, <span class=SpellE>Merschhemke</span>
M, Li B, <span class=SpellE>Putzki</span> N, Liu FC, <span class=SpellE>Häring</span>
DA, <span class=SpellE>Kappos</span> L; INFORMS study investigators. Oral
fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, <span
class=SpellE>randomised</span>, double-blind, placebo-controlled trial. Lancet.
2016 Mar 12;387(10023):1075-1084. <span class=SpellE>doi</span>:
10.1016/S0140-6736(15)01314-8. <span class=SpellE>Epub</span> 2016 Jan 28.
Erratum in: Lancet. 2017 Jan 21;389(10066):254. PubMed PMID: 26827074.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>7.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]>Cohen
J, <span class=SpellE>Belova</span> A, <span class=SpellE>Selmaj</span> K, Wolf
C, <span class=SpellE>Sormani</span> MP, <span class=SpellE>Oberyé</span> J,
van den Tweel E, Mulder R, Koper N, Voortman G, <span class=SpellE>Barkhof</span>
F; Glatiramer Acetate Clinical Trial to Assess Equivalence <span class=GramE>With</span>
Copaxone (GATE) Study Group. Equivalence of Generic Glatiramer Acetate in
Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2015
Dec;72(12):1433-41. <span class=SpellE>doi</span>:
10.1001/jamaneurol.2015.2154. PubMed PMID: 26458034.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>8.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
class=SpellE>Calabresi</span> PA, <span class=SpellE>Kieseier</span> BC, Arnold
DL, <span class=SpellE>Balcer</span> LJ, Boyko A, Pelletier J, Liu S, Zhu Y, <span
class=SpellE>Seddighzadeh</span> A, Hung S, <span class=SpellE>Deykin</span> <span
class=GramE>A;</span> ADVANCE Study Investigators. Pegylated interferon
&#946;-1a for relapsing-remitting multiple sclerosis (ADVANCE): a <span
class=SpellE>randomised</span>, phase 3, double-blind study. Lancet Neurol.
2014 Jul;13(7):657-65. <span class=SpellE>doi</span>:
10.1016/S1474-4422(14)70068-7. <span class=SpellE>Epub</span> 2014 Apr 30.
PubMed PMID: 24794721.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>9.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
class=SpellE>Calabresi</span> PA, <span class=SpellE>Radue</span> EW, <span
class=SpellE>Goodin</span> D, Jeffery D, <span class=SpellE>Rammohan</span> KW,
<span class=SpellE>Reder</span> AT, Vollmer T, <span class=SpellE>Agius</span>
MA, <span class=SpellE>Kappos</span> L, <span class=SpellE>Stites</span> T, Li
B, <span class=SpellE>Cappiello</span> L, von Rosenstiel P, Lublin FD. Safety
and efficacy of fingolimod in patients with relapsing-remitting multiple
sclerosis (FREEDOMS II): a double-blind, <span class=SpellE>randomised</span>,
placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun;13(6):545-56. <span
class=SpellE>doi</span>: 10.1016/S1474-4422(14)70049-3. <span class=SpellE>Epub</span>
2014 Mar 28. Erratum in: Lancet Neurol. 2013 Jun;13(6):536. PubMed PMID:
24685276.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>10.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Vollmer
TL, Sorensen PS, <span class=SpellE>Selmaj</span> K, Zipp F, <span
class=SpellE>Havrdova</span> E, Cohen JA, <span class=SpellE>Sasson</span> N, <span
class=SpellE>Gilgun-Sherki</span> Y, Arnold DL; BRAVO Study Group. A randomized
placebo-controlled phase III trial of oral <span class=SpellE>laquinimod</span>
for multiple sclerosis. J Neurol. 2014 Apr;261(4):773-83. <span class=SpellE>doi</span>:
10.1007/s00415-014-7264-4. <span class=SpellE>Epub</span> 2014 Feb 18. PubMed
PMID: 24535134.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>11.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
class=SpellE>Confavreux</span> C, O'Connor P, <span class=SpellE>Comi</span> G,
Freedman MS, Miller AE, Olsson TP, <span class=SpellE>Wolinsky</span> JS, <span
class=SpellE>Bagulho</span> T, <span class=SpellE>Delhay</span> JL, <span
class=SpellE>Dukovic</span> D, <span class=SpellE>Truffinet</span> P, <span
class=SpellE>Kappos</span> L; TOWER Trial Group. Oral teriflunomide for
patients with relapsing multiple sclerosis (TOWER): a <span class=SpellE>randomised</span>,
double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014
Mar;13(3):247-56. <span class=SpellE>doi</span>: 10.1016/S1474-4422(13)70308-9.
<span class=SpellE>Epub</span> 2014 Jan 23. PubMed PMID: 24461574.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>12.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
class=SpellE>Vermersch</span> P, <span class=SpellE>Czlonkowska</span> A,
Grimaldi LM, <span class=SpellE>Confavreux</span> C, <span class=SpellE>Comi</span>
G, <span class=SpellE>Kappos</span> L, Olsson TP, <span class=SpellE>Benamor</span>
M, Bauer D, <span class=SpellE>Truffinet</span> P, Church M, Miller AE, <span
class=SpellE>Wolinsky</span> JS, Freedman MS, O'Connor P; TENERE Trial Group.
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing
multiple sclerosis: a <span class=SpellE>randomised</span>, controlled phase 3
trial. <span class=SpellE>Mult</span> <span class=SpellE>Scler</span>. 2014
May;20(6):705-16. <span class=SpellE>doi</span>: 10.1177/1352458513507821. <span
class=SpellE>Epub</span> 2013 Oct 14. PubMed PMID: 24126064.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>13.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Lublin
FD, Cofield SS, Cutter GR, <span class=SpellE>Conwit</span> R, Narayana PA,
Nelson F, Salter AR, Gustafson T, <span class=SpellE>Wolinsky</span> JS; <span
class=SpellE>CombiRx</span> Investigators. Randomized study combining interferon
and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013
Mar;73(3):327-40. <span class=SpellE>doi</span>: 10.1002/ana.23863. <span
class=SpellE>Epub</span> 2013 Mar 11. PubMed PMID: 23424159; PubMed Central
PMCID: PMC3631288.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>14.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Cohen
JA, Coles AJ, Arnold DL, <span class=SpellE>Confavreux</span> C, Fox EJ,
Hartung HP, <span class=SpellE>Havrdova</span> E, <span class=SpellE>Selmaj</span>
KW, Weiner HL, Fisher E, <span class=SpellE>Brinar</span> VV, <span
class=SpellE>Giovannoni</span> G, <span class=SpellE>Stojanovic</span> M, <span
class=SpellE>Ertik</span> BI, Lake SL, Margolin DH, <span class=SpellE>Panzara</span>
MA, <span class=SpellE>Compston</span> DA; CARE-MS I investigators. Alemtuzumab
versus interferon beta 1a as first-line treatment for patients with relapsing-remitting
multiple sclerosis: a <span class=SpellE>randomised</span> controlled phase 3
trial. Lancet. 2012 Nov 24;380(9856):1819-28. <span class=SpellE>doi</span>:
10.1016/S0140-6736(12)61769-3. <span class=SpellE>Epub</span> 2012 Nov 1.
PubMed PMID: 23122652.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>15.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Coles
AJ, Twyman CL, Arnold DL, Cohen JA, <span class=SpellE>Confavreux</span> C, Fox
EJ, Hartung HP, <span class=SpellE>Havrdova</span> E, <span class=SpellE>Selmaj</span>
KW, Weiner HL, Miller T, Fisher E, <span class=SpellE>Sandbrink</span> R, Lake
SL, Margolin DH, <span class=SpellE>Oyuela</span> P, <span class=SpellE>Panzara</span>
MA, <span class=SpellE>Compston</span> DA; CARE-MS II investigators.
Alemtuzumab for patients with relapsing multiple sclerosis after
disease-modifying therapy: a <span class=SpellE>randomised</span> controlled
phase 3 trial. Lancet. 2012 Nov 24;380(9856):1829-39. <span class=SpellE>doi</span>:
10.1016/S0140-6736(12)61768-1. <span class=SpellE>Epub</span> 2012 Nov 1.
PubMed PMID: 23122650.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>16.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Gold
R, <span class=SpellE>Kappos</span> L, Arnold DL, Bar-Or A, <span class=SpellE>Giovannoni</span>
G, <span class=SpellE>Selmaj</span> K, <span class=SpellE>Tornatore</span> C,
Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators.
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple
sclerosis.<span style='mso-spacerun:yes'>  </span>N <span class=SpellE>Engl</span>
J Med. 2012 Sep 20;367(12):1098-107. Erratum in: N <span class=SpellE>Engl</span>
J Med. 2012 Dec 13;367(24):2362. PubMed PMID: 22992073.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>17.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Fox
RJ, Miller DH, Phillips JT, Hutchinson M, <span class=SpellE>Havrdova</span> E,
Kita M, Yang M, <span class=SpellE>Raghupathi</span> K, <span class=SpellE>Novas</span>
M, Sweetser MT, <span class=SpellE>Viglietta</span> V, Dawson KT; CONFIRM Study
Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in
multiple sclerosis. N <span class=SpellE>Engl</span> J Med. 2012 Sep 20;367(12):1087-97.
Erratum in: N <span class=SpellE>Engl</span> J Med. 2012 Oct 25;367(17):1673.
PubMed PMID: 22992072.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>18.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Saida
T, Kikuchi S, <span class=SpellE>Itoyama</span> Y, Hao Q, Kurosawa T, Nagato K,
Tang D, Zhang-<span class=SpellE>Auberson</span> L, Kira J. A randomized,
controlled trial of fingolimod (FTY720) in Japanese patients with multiple
sclerosis. <span class=SpellE>Mult</span> <span class=SpellE>Scler</span>. 2012
Sep;18(9):1269-77. <span class=SpellE>doi</span>: 10.1177/1352458511435984. <span
class=SpellE>Epub</span> 2012 Feb 21. PubMed PMID: 22354739.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>19.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
class=SpellE>Kappos</span> L, Li D, <span class=SpellE>Calabresi</span> PA,
O'Connor P, Bar-Or A, <span class=SpellE>Barkhof</span> F, Yin M, <span
class=SpellE>Leppert</span> D, <span class=SpellE>Glanzman</span> R, Tinbergen
J, Hauser SL. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2,
<span class=SpellE>randomised</span>, placebo-controlled, <span class=SpellE>multicentre</span>
trial. Lancet. 2011 Nov 19;378(9805):1779-87. <span class=SpellE>doi</span>:
10.1016/S0140-6736(11)61649-8. <span class=SpellE>Epub</span> 2011 Oct 31.
PubMed PMID: 22047971.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>20.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>O'Connor
P, <span class=SpellE>Wolinsky</span> JS, <span class=SpellE>Confavreux</span>
C, <span class=SpellE>Comi</span> G, <span class=SpellE>Kappos</span> L, Olsson
TP, <span class=SpellE>Benzerdjeb</span> H, <span class=SpellE>Truffinet</span>
P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. Randomized trial of oral
teriflunomide for relapsing multiple sclerosis. N <span class=SpellE>Engl</span>
J Med. 2011 Oct 6;365(14):1293-303. <span class=SpellE>doi</span>:
10.1056/NEJMoa1014656. PubMed PMID: 21991951.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>21.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Cohen
JA, <span class=SpellE>Barkhof</span> F, <span class=SpellE>Comi</span> G,
Hartung HP, Khatri BO, <span class=SpellE>Montalban</span> X, Pelletier J,
Capra R, Gallo P, <span class=SpellE>Izquierdo</span> G, <span class=SpellE>Tiel-Wilck</span>
K, de Vera A, <span class=SpellE>Jin</span> J, <span class=SpellE>Stites</span>
T, Wu S, <span class=SpellE>Aradhye</span> S, <span class=SpellE>Kappos</span>
L; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for
relapsing multiple sclerosis. N <span class=SpellE>Engl</span> J Med. 2010 Feb
4;362(5):402-15. <span class=SpellE>doi</span>: 10.1056/NEJMoa0907839. <span
class=SpellE>Epub</span> 2010 Jan 20. PubMed PMID: 20089954.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>22.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
class=SpellE>Kappos</span> L, <span class=SpellE>Radue</span> EW, O'Connor P,
Polman C, <span class=SpellE>Hohlfeld</span> R, <span class=SpellE>Calabresi</span>
P, <span class=SpellE>Selmaj</span> K, <span class=SpellE>Agoropoulou</span> C,
<span class=SpellE>Leyk</span> M, Zhang-<span class=SpellE>Auberson</span> L, <span
class=SpellE>Burtin</span> P; FREEDOMS Study Group. A placebo-controlled trial
of oral fingolimod in relapsing multiple sclerosis. N <span class=SpellE>Engl</span>
J Med. 2010 Feb 4;362(5):387-401. <span class=SpellE>doi</span>:
10.1056/NEJMoa0909494. <span class=SpellE>Epub</span> 2010 Jan 20. PubMed PMID:
20089952.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>23.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Hawker
K, O'Connor P, Freedman MS, <span class=SpellE>Calabresi</span> PA, <span
class=SpellE>Antel</span> J, Simon J, Hauser S, <span class=SpellE>Waubant</span>
E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH; OLYMPUS trial group.
Rituximab in patients with primary progressive multiple sclerosis: results of a
randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009
Oct;66(4):460-71. <span class=SpellE>doi</span>: 10.1002/ana.21867. PubMed
PMID: 19847908.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>24.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>O'Connor
P, <span class=SpellE>Filippi</span> M, <span class=SpellE>Arnason</span> B, <span
class=SpellE>Comi</span> G, Cook S, <span class=SpellE>Goodin</span> D, Hartung
HP, Jeffery D, <span class=SpellE>Kappos</span> L, Boateng F, <span
class=SpellE>Filippov</span> V, <span class=SpellE>Groth</span> M, <span
class=SpellE>Knappertz</span> V, Kraus C, <span class=SpellE>Sandbrink</span>
R, Pohl C, <span class=SpellE>Bogumil</span> T; BEYOND Study Group, O'Connor P,
<span class=SpellE>Filippi</span> M, <span class=SpellE>Arnason</span> B, Cook
S, <span class=SpellE>Goodin</span> D, Hartung HP, <span class=SpellE>Kappos</span>
L, Jeffery D, <span class=SpellE>Comi</span> G. 250 microg or 500 microg
interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting
multiple sclerosis: a prospective, <span class=SpellE>randomised</span>,
multicenter study. Lancet Neurol. 2009 Oct;8(10):889-97. <span class=SpellE>doi</span>:
10.1016/S1474-4422(09)70226-1. <span class=SpellE>Epub</span> 2009 Sep 2.
Erratum in: Lancet Neurol. 2009 Nov;8(11):981. Lancet Neurol. 2011
Feb;10(2):115. Lancet Neurol. 2012 Jan;11(1):27. Cree, B [added]; <span
class=SpellE>Harung</span>, H-P [corrected to Hartung, H-P]. PubMed PMID:
19729344.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>25.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>CAMMS223
Trial Investigators, Coles AJ, <span class=SpellE>Compston</span> DA, <span
class=SpellE>Selmaj</span> KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon
PK. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N <span
class=SpellE>Engl</span> J Med. 2008 Oct 23;359(17):1786-801. <span
class=SpellE>doi</span>: 10.1056/NEJMoa0802670. PubMed PMID: 18946064.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>26.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
class=SpellE>Mikol</span> DD, <span class=SpellE>Barkhof</span> F, Chang P,
Coyle PK, Jeffery DR, <span class=SpellE>Schwid</span> SR, <span class=SpellE>Stubinski</span>
B, <span class=SpellE>Uitdehaag</span> B; REGARD study group. Comparison of
subcutaneous interferon beta-1a with glatiramer acetate in patients with
relapsing multiple sclerosis (the <span class=SpellE>REbif</span> vs Glatiramer
Acetate in Relapsing MS Disease [REGARD] study): a <span class=SpellE>multicentre</span>,
<span class=SpellE>randomised</span>, parallel, open-label trial. Lancet
Neurol. 2008 Oct;7(10):903-14. <span class=SpellE>doi</span>: 10.1016/S1474-4422(08)70200-X.
<span class=SpellE>Epub</span> 2008 Sep 11. PubMed PMID: 18789766.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>27.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Hauser
SL, <span class=SpellE>Waubant</span> E, Arnold DL, Vollmer T, <span
class=SpellE>Antel</span> J, Fox RJ, Bar-Or A, <span class=SpellE>Panzara</span>
M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group. B-cell
depletion with rituximab in relapsing-remitting multiple sclerosis. N <span
class=SpellE>Engl</span> J Med. 2008 Feb 14;358(7):676-88. <span class=SpellE>doi</span>:
10.1056/NEJMoa0706383. PubMed PMID: 18272891.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>28.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
class=SpellE>Wolinsky</span> JS, Narayana PA, O'Connor P, Coyle PK, Ford C,
Johnson K, Miller A, Pardo L, <span class=SpellE>Kadosh</span> S, <span
class=SpellE>Ladkani</span> D; <span class=SpellE>PROMiSe</span> Trial Study Group.
Glatiramer acetate in primary progressive multiple sclerosis: results of a
multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol.
2007 Jan;61(1):14-24. PubMed PMID: 17262850.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>29.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
class=SpellE>Etemadifar</span> M, <span class=SpellE>Janghorbani</span> M, <span
class=SpellE>Shaygannejad</span> V. Comparison of <span class=SpellE>Betaferon</span>,
Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta
Neurol Scand. 2006 May;113(5):283-7. PubMed PMID: 16629762.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>30.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>O'Connor
PW, Li D, Freedman MS, Bar-Or A, Rice GP, <span class=SpellE>Confavreux</span>
C, <span class=SpellE>Paty</span> DW, Stewart JA, <span class=SpellE>Scheyer</span>
R; Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia
MS/MRI Research Group. A Phase II study of the safety and efficacy of
teriflunomide in multiple sclerosis with relapses. Neurology. 2006 Mar
28;66(6):894-900. PubMed PMID: 16567708.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>31.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Polman
CH, O'Connor PW, <span class=SpellE>Havrdova</span> E, Hutchinson M, <span
class=SpellE>Kappos</span> L, Miller DH, Phillips JT, Lublin FD, <span
class=SpellE>Giovannoni</span> G, <span class=SpellE>Wajgt</span> A, <span
class=SpellE>Toal</span> M, Lynn F, <span class=SpellE>Panzara</span> MA, <span
class=SpellE>Sandrock</span> AW; AFFIRM Investigators. A randomized,
placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N <span
class=SpellE>Engl</span> J Med. 2006 Mar 2;354(9):899-910. PubMed PMID:
16510744.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>32.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Panitch
H, Miller A, <span class=SpellE>Paty</span> D, <span class=SpellE>Weinshenker</span>
B; North American Study Group on Interferon beta-1b in Secondary Progressive
MS. Interferon beta-1b in secondary progressive MS: results from a 3-year
controlled study. Neurology. 2004 Nov 23;63(10):1788-95. PubMed PMID: 15557491.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>33.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Andersen
O, <span class=SpellE>Elovaara</span> I, <span class=SpellE>Färkkilä</span> M,
Hansen HJ, <span class=SpellE>Mellgren</span> SI, <span class=SpellE>Myhr</span>
KM, Sandberg-<span class=SpellE>Wollheim</span> M, <span class=SpellE>Soelberg</span>
<span class=SpellE>Sørensen</span> P. <span class=SpellE>Multicentre</span>, <span
class=SpellE>randomised</span>, double blind, placebo controlled, phase III
study of weekly, low dose, subcutaneous interferon beta-1a in secondary
progressive multiple sclerosis. J Neurol <span class=SpellE>Neurosurg</span>
Psychiatry. 2004 May;75(5):706-10. PubMed PMID: 15090564; PubMed Central PMCID:
PMC1763573.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>34.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Miller
DH, Khan OA, <span class=SpellE>Sheremata</span> WA, <span class=SpellE>Blumhardt</span>
LD, Rice GP, <span class=SpellE>Libonati</span> MA, <span class=SpellE>Willmer</span>-Hulme
AJ, Dalton CM, <span class=SpellE>Miszkiel</span> KA, O'Connor PW;
International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of
natalizumab for relapsing multiple sclerosis. N <span class=SpellE>Engl</span>
J Med. 2003 Jan 2;348(1):15-23. PubMed PMID: 12510038.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>35.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Panitch
H, <span class=SpellE>Goodin</span> DS, Francis G, Chang P, Coyle PK, O'Connor
P, Monaghan E, Li D, <span class=SpellE>Weinshenker</span> B; EVIDENCE Study
Group. <span class=SpellE>EVidence</span> of Interferon Dose-response: <span
class=SpellE>Europian</span> North American <span class=SpellE>Compartative</span>
Efficacy; University of British Columbia MS/MRI Research Group. Randomized,
comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE
Trial. Neurology. 2002 Nov 26;59(10):1496-506. PubMed PMID: 12451188.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>36.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
class=SpellE>Durelli</span> L, Verdun E, <span class=SpellE>Barbero</span> P, <span
class=SpellE>Bergui</span> M, <span class=SpellE>Versino</span> E, <span
class=SpellE>Ghezzi</span> A, <span class=SpellE>Montanari</span> E, <span
class=SpellE>Zaffaroni</span> M; Independent Comparison of Interferon (INCOMIN)
Trial Study Group. Every-other-day interferon beta-1b versus once-weekly
interferon beta-1a for multiple sclerosis: results of a 2-year prospective <span
class=SpellE>randomised</span> <span class=SpellE>multicentre</span> study (INCOMIN).
Lancet. 2002 Apr 27;359(9316):1453-60. PubMed PMID: 11988242.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>37.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
class=SpellE>Randomised</span> double-blind placebo-controlled study of
interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS
(Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in
Multiple Sclerosis) Study Group. Lancet. 1998 Nov 7;352(9139):1498-504. Erratum
in: Lancet 1999 Feb 20;353(9153):678. PubMed PMID: 9820297.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>38.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Johnson
KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, <span class=SpellE>Lisak</span>
RP, Myers LW, Panitch HS, Rose JW, Schiffer RB. Copolymer 1 reduces relapse
rate and improves disability in relapsing-remitting multiple sclerosis: results
of a phase III multicenter, double-blind placebo-controlled trial. The
Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995 Jul;45(7):1268-76.
PubMed PMID: 7617181.<o:p></o:p></p>

<p class=MsoListParagraph style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;line-height:107%;mso-list:l0 level1 lfo1'><![if !supportLists]><span
style='mso-fareast-font-family:Calibri'><span style='mso-list:Ignore'>39.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Interferon
beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical
results of a multicenter, randomized, double-blind, placebo-controlled trial.
The IFNB Multiple Sclerosis Study Group. Neurology. 1993 Apr;43(4):655-61.
PubMed PMID: 8469318.<o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

</div>

</body>

</html>
